Strong Q1 profit growth; expansion on track despite Raipur drag

Delivered ₹287.3 Cr, +12.7% YoY. Gurgaom standalone +15.4%.

21.5% of ₹287.3 = ₹61.8 Cr ✓; PAT ₹31.4 Cr confirmed; growth rate matches.

Occupancy improving; occupancy constraint cited as rationale for Tower IV expansion. Q2 reaffirmation of prior 70% target.

Soft launch 9 July (OPD), full ops 27 July (theaters/cath labs). Complex surgeries (commando) happening. ₹20 Cr loss estimate aligns with prior ₹18–20 Cr guidance.

27% reported; no single regional dependency; Q2 guidance realistic given diversification strategy.

Quantified margin target new; revenue model (70% occupancy, 85% census, 4–5% ARPOB growth) provided by analyst, confirmed by MD.

Capex ₹120 Cr total; 50% occupancy by 6 mo, full breakeven 8–10 mo post-launch. Timelines consistent.

Complex surgeries (commando oncology) already live at 3 weeks vs. expected phased ramp. OPD, cath labs, neurosurgery operational together. Suggests faster patient acquisition feasible.

Originally implied multi-specialty expansion; now positioned as dedicated pediatric tertiary/quaternary + obstetrics/gynecology tower to become 'nodal referral center for NCR.' Marketing/positioning shift, not economics.

Prior calls implied sustained hub-and-spoke model. Now: 'consolidate within 3–4 years'; smaller centers have capacity constraints limiting growth. Strategic pivot away from saturation via independent satellite centers.

Raipur insurance 8–10 weeks expected vs. prior 3–4 months industry norm. Benefit of provider-payer CII platform mediation (MD co-chairing working group). Supports faster ramp but execution risk remains.

27% in Q1 despite war; no single regional dependency; multi-country sourcing; Q2 target 30%. Overall volume not compromised vs. peers.

Combined: 130–150 beds from platinum rating free + 70 beds FAR purchased = 200+ total. Timeline 18–22 months.

Yes, absolutely. Economies of scale, case mix improvement, manpower efficiency drive expansion.

Encouraging: OPD 9 July, theaters 27 July, complex surgeries live. 15–18 mo to break-even, ₹20 Cr loss. Occupancy early; detailed Q2 update promised.

Economies of scale (fixed costs spread), case mix improvement (ARPOB highest in NCR), smaller centers + cardiac improving. Adding 200 beds will expand margins further.

All major specialties live simultaneously: advanced cath lab, EP, neurosurgery, onco, trauma. Total capex ₹120 Cr (80% done). PET-CT & radiotherapy finishing by end-Aug.

No separate team; already doing tertiary/quaternary pediatric care in-house. Tower IV consolidates under one roof for brand positioning, not new capability.

No; Gurgaom will reach 70–72% occupancy by end-FY27, so Tower IV beds will absorb demand without patient denial. No net occupancy loss.

6–8 months for asset finalization before launch. Enabling resolution; quantum & timing fluid based on asset quality & shareholder dilution.

Tower IV ₹55 lakhs/bed (all-in). Total ₹800 Cr capex over 3 years (Raipur ₹120 Cr, VIMHANS ₹350–360 Cr, Tower IV ₹120 Cr, parking ₹70–80 Cr, replacement ₹100–120 Cr).

Deferred to offline email for detailed segment data.

8–10 weeks expected (faster than 3–4 mo norm) via CII provider-payer platform. TPA intermediary bridging cashless experience until direct empanelment.

Gurgaom has most intense bed competition; we've grown 90→600+ beds via outcomes & ethics. Tower IV showcases tertiary/quaternary services beyond standalone pediatric hospitals' capacity.

900 minimum (700+200), 980 maximum post-detailed architectural drawings. Raipur traction growing; insurance 8–10 weeks; occupancy targets deferred to Q2 call.

Enabling resolution; new brownfield acquisitions only (not Raipur/Tower IV/VIMHANS, which are self-funded via accruals & debt). Focus on EBITDA break-even or positive brownfields.

Hub-and-spoke model initially working; now consolidating centers after maturity (3–4 years) to improve bed economics. No breakup details given.

Planning 75 years; full organogram details deferred to offline with Rudra (central teams, regional teams, zonal areas, controls defined).

Break-even 8–10 months post-launch (likely H2 FY28 if 18–22 mo operationalization). 50% occupancy by 6 months expected.

₹450 Cr from accruals over 3 years covers announced projects + debt leverage. QIP for brownfield M&A only to minimize shareholder dilution; thought-through process.

Yes, on track for 70% Q2. At 85% census, 70% occupancy, 4–5% ARPOB growth over 3–5 years, ₹2,000 Cr from Gurgaom alone possible with 23%+ margins.

Capacity constraints in smaller units; hub-and-spoke model served purpose but will consolidate. Rents & manpower outpace topline in limited-bed settings; 3–4 year maturation before consolidation.

Deposit (₹250 Cr, ₹130 Cr paid) separate from ₹800 Cr capex. Raipur ₹120 Cr, VIMHANS ₹350–360 Cr pure capex, Tower IV ₹120 Cr, parking ₹70–80 Cr, replacement ₹100–120 Cr. Totals ₹600 Cr.

Q1 delivered +15.4% standalone; occupancy 65.7%→70% Q2 on track; Tower IV break-even 8–10 mo supports growth ladder.

FY29–30 target; assumes 900–950 beds, 70% occupancy, 85% census, 4–5% ARPOB growth. Analyst-driven model, MD confirmed feasible. Execution risk: multi-year horizon.

Expected ₹20 Cr loss; complex surgeries early suggests faster ramp possible. Insurance empanelment (8–10 weeks) critical to revenue trajectory. Timeline: likely Q4 FY28–Q1 FY29.

Q1 delivered 21.5% consolidated (Gurgaom higher). Confirmed achievable by MD; economies of scale + case mix.

Tower IV + 200-bed expansion, higher-margin pediatric/obstetric focus, manpower efficiency drive upside. Conservative: assumes modest incremental margin expansion from 21.5% current.

Raipur loss will compress consolidated margins near-term. Offset by Gurgaom expansion & Tower IV. Net margin trajectory: neutral-to-positive by FY29.

Raipur ₹120 Cr, VIMHANS ₹350–360 Cr, Tower IV ₹120 Cr, parking ₹70–80 Cr, replacement ₹100–120 Cr. Deposits (VIMHANS) ₹250 Cr separate.

Brownfield expansion significantly cheaper than greenfield (₹120 lakhs/bed). Parking inclusion inflates per-bed but reflects infrastructure priorities.

Acquisition-in-progress; deposit ₹130 Cr paid. Capital-intensive; integration timeline multi-year. South Delhi presence unlocks hub-and-spoke model.

Raipur just 3 weeks old; occupancy trajectory unproven. Management cautious ('very early days'). Break-even 15–18 months assumes steady state; any slip extends loss period.

Raipur insurance critical to patient ramp. Management targeting 8–10 weeks but relies on CII provider-payer platform & IRDA coordination. TPA intermediary is lower-yield bridge.

Q1 occupancy 65.7%; management cites 'inflection point' requiring Tower IV to prevent patient denial. If demand slower than assumed, capex return questioned. If faster, Q2 target 70% delays full ramp.

Daffodils, Artemis Lite, Cardiac Care muted in Q1 (analyst back-calc). Strategy to consolidate after maturity (3–4 years) signals current units unprofitable or low-margin. Q1 drag material if larger than expected.

Rainbow Children's entering Gurgaom with dedicated pediatric focus. Tower IV positions Artemis as tertiary/quaternary pediatric center, but standalone competitors may appeal on specialization.

Dr. Devlina MD for 20+ years; planning to 75. Multi-city model (Raipur, South Delhi, Tower IV) requires distributed management & central controls. Organogram details deferred; succession plan unclear.